For example, one tier would consist experimentally validated driver combinations, such as BRAF + PTEN in melanomas and ATRX + IDH1 + TP53 in gliomas, and lower tiers would consist of computationally predicted combinations nominated by methods such as CRSO and SELECT, with varying amount of literature support. The gene discussed is ATRX; the disease is glioma.